The story of Viagra presents a challenging picture for shareholders. While the initial release generated substantial profits, the end of its exclusive rights opened the door to cheaper versions, dramatically diminishing revenue. This creates a specific risk for drug manufacturers relying on related blockbuster products, suggesting that a unquestion

The history of Viagra, and its developer copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in income, its exclusivity period created a deluge of lower-priced alternatives , significantly impacting its position . While some pharmaceutical companies may try to capitalize on similar conditions ,